IMPORTANCE Combined-modality therapy with chemotherapy and radiation therapy plays a crucial role in the upfront treatment of patients with limited-stage small cell lung cancer (SCLC), but there may be barriers to utilization in the United States.
A pproximately 15% to 30% of lung cancers are small cell lung cancer (SCLC), and one-third of cases are diagnosed in the limited stage. 1 Since 1989, the International Association for the Study of Lung Cancer has defined limited-stage SCLC (LS-SCLC) as the absence of metastatic disease. 2 For LS-SCLC, initial management with concurrent chemotherapy and thoracic radiation therapy is the standard of care in the United States. 3 Multiple prospective trials established the efficacy of thoracic chemoradiation for LS-SCLC, 4-8 which was further corroborated by the 1992 metaanalysis by Pignon et al. 9 Even delays in thoracic radiation therapy compromise outcomes, 10-12 supporting use of thoracic radiation therapy by the third cycle of chemotherapy.
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The National Cancer Database (NCDB) is a valuable resource for understanding patterns of care for LS-SCLC. 14, 15 We have analyzed the initial treatment of patients with LS-SCLC in the NCDB and determined variables associated with combined-modality therapy delivery and survival, with the hypothesis that there are barriers to combined-modality delivery such as insurance status that adversely affect survival.
Methods
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. Data used in this study are derived from a deidentified NCDB file not subject to institutional review board review or requirement for informed consent. Adult (≥18 years) patients with SCLC diagnosed from 2004 through 2013 were retrieved from the NCDB using the International Classification of Diseases for Oncology, Third Edition, codes for invasive SCLC (8041/3-8045/3), totaling 202 191 patients. Selection criteria included absence of clinical or pathological evidence of metastatic disease (American Joint Committee on Cancer [AJCC] 6th or 7th edition) at diagnosis (n = 122 544 [60.6%]), and missing data entries for metastatic disease were also excluded (n = 2583 [1.3%]). Patients without follow-up were excluded (n = 20 407 [10.1%]). Survival curves were generated using the Kaplan-Meier method, and overall survival was compared with log-rank tests. Median follow-up was estimated by reverse Kaplan-Meier method. Multivariable analysis (MVA) was conducted using Cox proportional hazard and binary logistic regression models. Clinical variables of interest were tested on univariate analysis and included in the MVA if clinically relevant and statistically significant (eTables 1-4 in the Supplement). Variance inflation factors and correlation matrix were used to identify significant colinearity in the MVA. All tests were 2 tailed, and statistical significance was considered for P < .05. Data analysis was performed by means of SPSS 24 software (IBM SPSS).
Results
From 2004 through 2013, there were 202 191 cases of SCLC captured in the NCDB. A total of 70 247 cases were identified with LS-SCLC, and baseline characteristics were determined (eTable 5intheSupplement). The patients were 55.3% female. Initial treatment was 55.5% chemotherapy and radiation therapy, 20.5% chemotherapy alone, 3.5% radiation therapy alone, 20% neither chemotherapy nor radiation therapy, and 0.5% not reported.
With median follow-up of 62.3 (95% CI, 62.3-64.1) months, survival was compared between the groups (Figure) . Patients who received chemotherapy and radiation had significantly better median survival (18.2 months; 95% CI, 17.9-18.4 months) than any other cohort (P < .001). Those who received chemotherapy or radiation alone had a median survival of 10.5 (95% CI, 10.3-10.7) and 8.3 (95% CI, 7.7-8.8) months, respectively. Patients who received neither chemotherapy nor radiation therapy had worse median survival (3.7 months; 95% CI, 3.5-3.8 months) in comparison with any other cohort (P < .001).
Lack of insurance (odds ratio [OR], 0.75; 95% CI, 0.67-0.85; P < .001), Medicaid (OR, 0.79; 95% CI, 0.72-0.87; P < .001), and Medicare (OR, 0.86; 95% CI, 0.82-0.91; P < .001) were independently associated with a lower likelihood of receiving radiation therapy in comparison with private or managed care insurance ( Table 1) . In evaluating factors associated with chemotherapy delivery, being uninsured (OR, 0.65; 95% 
Key Points
Question What barriers affect utilization of combined-modality therapy for limited-stage small cell lung cancer (SCLC)?
Findings In this analysis of National Cancer Database data, substantial proportions of patients did not receive chemotherapy (23%) or radiation therapy (41%) for limited-stage SCLC. Government insurance (Medicaid or Medicare) had no effect on chemotherapy administration but was independently associated with a lower likelihood of radiation therapy delivery, which was in turn, associated with worse survival.
Meaning
There are substantial barriers to standard-of-care therapy for limited-stage SCLC such as government insurance.
CI, 0.56-0.75; P < .001) was associated with a lower likelihood of chemotherapy delivery, but neither Medicaid on univariate analysis (OR, 1.01; 95% CI, 0.92-1.10; P = .86) nor Medicare insurance on MVA (OR, 0.97; 95% CI, 0.91-1.03; P = .36) was associated with chemotherapy delivery.
Multiple socioeconomic factors were highly associated with overall survival on MVA ( Table 2) . Treatment at a community cancer program (HR, 1.19; 95% CI, 1.16-1.23; P < .001), comprehensive community cancer program (HR, 1.08; 95% CI, 1.06-1.11; P < .001), or integrated cancer program (HR, 1.07; 95% CI, 1.03-1.12; P = .001) was associated with a survival detriment in comparison with academic/research programs. Being uninsured (HR, 1.19; 95% CI, 1.13-1.26; P < .001), Medicaid insurance (HR, 1.27; 95% CI, 1.21-1.32; P < .001), and Medicare insurance (HR, 1.12; 95% CI, 1.09-1.15; P < .001) were also independently associated with worse survival. Delivery of chemotherapy (HR, 0.55; 95% CI, 0.54-0.57; P < .001) and radiation therapy (HR, 0.62; 95% CI, 0.60-0.63; P < .001) remained highly associated with a survival advantage for LS-SCLC on MVA. 
Discussion
This NCDB registry analysis provides large-scale documentation of factors associated with combined-modality utilization and survival for LS-SCLC, highlighting major barriers to standard of care such as insurance status. These findings also shed light on challenges seen with clinical trial enrollment for LS-SCLC. A key finding in this study was that government insurance (Medicare/Medicaid) had no impact on chemotherapy administration but was independently associated with lower likelihood of radiation therapy delivery and worse survival. This suggests that programs such as 340b and the Medicaid Drug Discount Program (that allow hospitals to deliver chemotherapy with competitive reimbursement) have improved chemotherapy access. However, these programs provide no financial assistance for radiation therapy delivery to this atrisk population, which may partially explain why patients with government insurance were significantly less likely to receive radiation therapy. As such, the relation of insurance status seen in this study to combined-modality delivery and survival is directly relevant to ongoing policy debate in the United States regarding the Medicaid program and affordable health care. Our findings suggest the need for targeted access improvement to radiation therapy for this population. Future study will be performed to identify specific geographic areas with deficiencies in combined-modality delivery to enable targeted access improvement.
We found that patients treated at academic centers had better survival than those treated in other practice settings.
Although there is accumulating evidence demonstrating improved outcomes at academic centers with non-small cell lung cancers, 16 we provide evidence of the same phenomenon in SCLC. While reasons for these differences in outcomes in different practice settings are not clear, possible explanations for better outcomes at academic centers include patient selection, coordination of care, and access to subspecialists.
Limitations
There are limitations of this analysis. There were a small proportion of cases with insufficient data or follow-up. The NCDB limits treatment data collected to the first course of treatment, so it is impossible to ascertain whether patients eventually went on to receive completion of their combinedmodality care. Additionally, while chemotherapy and radiation therapy are reported, the NCDB does not provide information on whether they were delivered concurrently or sequentially. Another important limitation of NCDB data is the lack of clarity on the completeness of oncologic staging. Last, as with any database, conclusions of the analysis are predicated on the accuracy of initial data input.
Conclusions
A substantial proportion of patients with LS-SCLC did not receive either radiation therapy or chemotherapy as part of their initial oncologic treatment, providing impetus for health care reform to improve access. 
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